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ABSTRACT: Molecularly targeted therapy is guided by an
understanding of relevant genetic variations among individuals
with a particular disease and, when applicable, by the relevant
molecular variations in the expression of that disease. This
approach has the potential to discriminate potential responders
from nonresponders, identify which patients are likely to bene-
fit earlier in the disease pathway, ensure appropriate dosing,
reduce incidence of adverse events, and improve overall health
gain. Stated otherwise, molecularly targeted therapy maximises
the number of appropriately treated patients while minimising
the number exposed to the treatment but in whom it ulti-
mately fails. The benefits, however, must be balanced against
the cost of screening tests to identify who is most likely to ben-
efit from targeted therapy and against the lifetime costs of
treatment.
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It is obvious that the status of pharmacoeconomics is now at a
critical point. The challenge to health care payors is that they
are confronted by the basic economic principle of resource scar-
city and infinite demands. Health care resources are limited and
pressure is increasing to contain the growth of overall health care
costs. Demand is driven by a combination of demographic
change, patient knowledge and new technologies. Patient
demand fuels the search for new technologies and increases
pressure on the reimbursement systems.
Consequently, economic theory is increasingly being applied
in health care decisions, specifically in regard to coverage for
new technologies. Currently, a large proportion of lifetime health
care expenditures occur at the end of life. Targeted therapies can
shift the economics from excessive end-of-life spending to
investing in prevention, earlier diagnosis, and early treatment of
chronic conditions, Fig. 1. The early stages of developing molecu-
larly targeted agents are likely to entail substantial investments
in diagnostics and prevention, but savings might accrue during
the later stages when diseases are prevented and/or treatments
are applied with greater efficiency.1
HEALTH TECHNOLOGY ASSESSMENT: Health technology
assessment (HTA) is a multidisciplinary process that summarises
information about the medical, social, economic and ethical con-
cerns related to the use of a health technology in a systematic,
transparent, unbiased and robust manner. Its aim is to inform
safe and effective health policies that are patient focused and
seek to achieve best value.2
Payors, whether they are governments or insurance compa-
nies, must be accountable to the taxpayers or policyholders
whowant to know that their contributions are used in an efficient
manner. However, even the most robust HTA is subject to uncer-
tainty from several sources, for example, the relationship
between surrogate endpoints and final outcomes, the relation-
ship between efficacy and effectiveness and resource use distri-
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Fig. 1 – Savings from use of molecularly targeted agents
could be invested in diagnostics development and cancer
prevention.
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butions (e.g. hospital stays). Therefore, estimates of uncertainty
must be factored into economic facets of HTAs.
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Industry, too, faces challenges as we enter the era of molecularly
targeted therapy. Investment in the research and development
can be significant, but a targeted therapy may be appropriate
for only a subset of patients who have the correct molecular tar-
get. Screening would eliminate patients for whom the treatment
would not be effective. As such, the development costs may
increase but the potential patient population may decrease.
Therefore, incentives need to be in place to ensure that manufac-
turers can realise a return on their investment.
Molecularly targeted therapy appears to offer an attractive
value proposition; however, this can only be realised if industrial
incentives are aligned with health care incentives. Introducing
these therapies into practice presents some challenges. ‘Both
strong intellectual property protections and value-based, flexible
pricing systems will be important in making personalised medi-
cine a reality.’2
Health care expenditures, both in absolute terms and as a per-
centage of gross domestic product (GDP) are growing around the
world. Innovative drugs are becoming more difficult to find, and
more expensive to develop. Together these present significant
challenges to both Payers and the Pharmaceutical Industry.
The challenge is developing successful next-generation oncol-
ogy drugs within this environment. Success may be defined in
several different ways. Success, to the patient, means access to
a treatment that works. For the physician, it means using the
right drugs in the right patients at the right time. Success, as
defined by payers, connotes affordability and value for monies
spent. Pharmaceutical companies seek success in the form of
payback on their investment in research and development.
According to the traditional view of drug development and
licensure, the product has three hurdles to negotiate: safety, effi-
cacy and quality. In reality, however, at least three additional hur-
dles must be surmounted: national pricing and reimbursement,
local/regional market access and health technology assessment
(HTA). These last three include financial pressures in their evalu-
ation. There is one additional challenge that must be considered
at the outset of the development process – the need to measure
value. To achieve success, pharmaceutical companies have to
demonstrate that a product will deliver value (to the patient,
and to the health economy) and net a return on their investment.
The highest hurdle is HTA, which has been defined as ‘a mul-
tidisciplinary process that summarises information about the
medical, social, economic and ethical issues related to the use
of a health technology in a systematic, transparent, unbiased,
robust manner. Its aim is to inform the formulation of safe, effec-
tive, health policies that are patient focused and seek to achieve
best value.’3 Nearly 50% of licensed therapies fail to fully sur-
mount the HTA hurdle in some way.
Not all drugs need to be subjected to the same levels of rigorous
evaluation. The amount and quality of evidence required for licen-
sure varies, and evidence required to support drug pricing and
market access follows a parallel track. For example, therapies that
are initially innovative (with price based on the value delivered)
are eventually joined in the market by other drugs that are thera-
peutically similar, resulting in cluster-based or reference pricing.
Payer–Industry partnerships could be an attractive, and poten-
tially successful approach in the future, as well (Fig. 1). Much
might be gained by leveraging complementary skills sets and
through access to, and analysis of, comprehensive (real-world)
treatment and outcomes data. Ultimately, payers and pharma-
ceutical firms are working for the same person – the patient.
SURMOUNTING THE HTA HURDLE: HTA poses a number of
questions regarding new therapies. First, how is the new treat-
ment or technology to be used? This line of questioning should
include the potential role or position of the therapy, the patients
most likely to benefit from it, when in the disease course should it
be used, and for how long. In addition to clinical-efficacy and –
effectiveness, questions of cost effectiveness and resource utilisa-
tion must be asked: How much does the therapy cost? Is it afford-
able? Does it represent acceptable ‘value for money’? (i.e. is it cost
effective?) What is the best way to allocate scarce resources? Eval-
uation of cost effectiveness is often one of the most important
components of HTA.
Key concepts often addressed are affordability, value for
money, and willingness to pay. Implicit are issues of rational
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Fig. 1 – Payer–industry partnership: an integrated approach.
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